Disease-Modifying MS Therapy in Primary-Progressive Disease

Multiple sclerosis (MS) classification now includes determination of disease activity and disease progression, regardless of the underlying MS subtype. Investigators retrospectively evaluated disease-modifying therapy (DMT) effectiveness in patients with primary-progressive (PP) MS patients with or without inflammatory activity. Out of a total of 3298 patients with PPMS, 665 met entry criteria for the ORATORIO trial of ocrelizumab, of whom 452 received a DMT. Because treated patients were younger and less disabled, 409 total patients were selected for propensity score matching.

Follow-up started when DMT use began or at first expanded disability status scale (EDSS) assessment if untreated. Mean follow-up was 11 years. The most common DMT was…